Study of Peanut Oral Immunotherapy for Children Aged 2 to 17 With Peanut Allergy Compared to Standard Avoidance

What this Trial Is About

Researchers are evaluating the real-world effectiveness, safety, and tolerability of peanut oral immunotherapy OIT in children aged 2 to 17 years with confirmed peanut allergy in Hong Kong. This open-label, non-randomized trial addresses the need for practical evidence beyond controlled clinical trials to make peanut OIT a more accessible option. The study also aims to identify biomarkers linked to successful treatment and to establish a model for future food allergy therapies in the region. Participants will be assigned to one of two groups an intervention group receiving 18 months of standardized peanut OIT using defatted peanut powder, or a control group following strict peanut avoidance for the same duration. Allocation is in a 41 ratio favoring the treatment group. The primary goal is to measure the proportion of children achieving desensitization to over 640 mg of peanut protein after 18 months. During the study, children will undergo oral food challenges to assess desensitization and have monitoring for treatment-related side effects. Researchers will systematically record adverse events and study reasons for discontinuation. Blood samples will be collected to analyze plasma protein biomarkers before and after treatment. The study will last 18 months per participant, with ongoing safety and efficacy assessments throughout.

Pathway to Peanut Tolerance